Valuation: Nectar Lifesciences Limited

Market Cap 1.81B 18.86M 16.57M 15.47M 14.2M 26.58M 27.23M 183M 71.74M 894M 70.82M 69.28M 3.09B P/E 2024
137x
P/E 2025 -4.53x
Enterprise Value 7.43B 77.56M 68.16M 63.62M 58.38M 109M 112M 754M 295M 3.68B 291M 285M 12.71B EV / Sales 2024
0.77x
EV / Sales 2025 0.64x
Free-Float
44.34%
Yield 2024 *
-
Yield 2025 -
07-11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
05-30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-06 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
03-02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
03-02 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
01-23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
01-06 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-20 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
12-03 Nectar Lifesciences approves buyback of shares valued at 810 million rupees RE
12-03 Nectar Lifesciences Limited Appoints Sushil Kapoor as Additional Director and Whole-Time Director, Effective December 4, 2025 CI
12-03 Nectar Lifesciences Limited announces an Equity Buyback for 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-03 Nectar Lifesciences Limited authorizes a Buyback Plan. CI
1 day+0.39%
1 week-4.49%
Current month-11.67%
1 month-10.51%
3 months-17.65%
6 months-26.32%
Current year-47.35%
1 week 10.01
Extreme 10.01
10.69
1 month 10.01
Extreme 10.01
11.99
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 14/11/2022
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 66 27/06/1995
Director/Board Member 69 11/02/2019
Director/Board Member 75 21/09/2021
Date Insider Type Main position Quantity % Market Cap.
19/12/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%-4.49%-38.32%-60.00% 20.7M
+0.67%+1.43%+16.90%+74.77% 49.64B
+1.05%+3.84%+64.12%+113.57% 36.54B
+2.06%+2.92%-6.22%+25.17% 12.22B
+2.14%-1.78%+14.55%+75.28% 11.48B
+1.05%+1.16%+31.33%+131.86% 9.04B
+3.08%+3.94%+50.54%-4.41% 6.94B
+0.17%-0.34%+12.61%+31.76% 6.74B
+3.53%+0.87%+5.47%+183.15% 6.45B
+0.61%-6.24%-32.70%-1.66% 5.42B
Average +1.48%-1.16%+11.83%+56.95% 14.45B
Weighted average by Cap. +1.24%+0.45%+26.64%+80.15%

Financials

2024 2025
Net sales 16.85B 176M 155M 144M 132M 248M 254M 1.71B 669M 8.34B 660M 646M 28.82B 16.7B 174M 153M 143M 131M 246M 252M 1.7B 663M 8.27B 655M 641M 28.57B
Net income 49.95M 521K 458K 428K 393K 735K 753K 5.07M 1.98M 24.72M 1.96M 1.92M 85.45M -1.14B -11.87M -10.43M -9.73M -8.93M -16.72M -17.14M -115M -45.14M -563M -44.56M -43.59M -1.94B
Net Debt 6.15B 64.23M 56.44M 52.68M 48.35M 90.51M 92.74M 625M 244M 3.04B 241M 236M 10.52B 5.62B 58.7M 51.58M 48.15M 44.19M 82.71M 84.75M 571M 223M 2.78B 220M 216M 9.62B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
1,786
Date Price Change Volume
29/07/26 10.22 +0.39% 102,074
28/07/26 ₹10.18 -2.21% 82,849
27/07/26 ₹10.41 +1.07% 56,490
24/07/26 ₹10.30 -0.58% 73,731
23/07/26 ₹10.36 -1.80% 76,356
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock